Jeffrey S. Johnson, Justin W. Miller, Firas Hatoum, Michael J. Schell, Xiaoqing Yu, Gabriel Roman Souza, Sarah Mizelle, Keerthi Gullapalli, Adnan Fazili, Rohit Jain, Jonathan Chatzkel, Ling Cen, Jasreman Dhillon, Christopher Cubitt, Jiqiang Yao, Junmin Whiting, Jiannong Li, Jennifer Swank, Ghazal Jameel, Jingsong Zhang, Xuefeng Wang, Philippe E. Spiess, Mayer Fishman, Jad Chahoud. "Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial." Nature Communications, 2026. doi:10.1038/s41467-026-73336-1